News
03-15-2010, 05:53 AM
YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.
More... (http://www.news-medical.net/news/20100315/YM-BioSciences-Two-posters-on-nimotuzumab-accepted-for-presentation-at-AACR.aspx)
More... (http://www.news-medical.net/news/20100315/YM-BioSciences-Two-posters-on-nimotuzumab-accepted-for-presentation-at-AACR.aspx)